Liminatus Pharma, Inc. amended its 8-K filing to provide an update on its business combination completed on April 30, 2025, including selected financial statements and details of stockholder redemptions amounting to approximately $702,359. The combined company, trading under new symbols on Nasdaq since May 1, 2025, reported an accumulated deficit of $28.7 million as of December 31, 2024.